Europe Epharmacy Market Research Report Forecast to 2027

Description

Europe Epharmacy Market Research Report Forecast To 2027

Market Overview
The growth of the Europe ePharmacy market is attributed to the rising occurrence of chronic and infectious diseases and an increase in the number of patients with multimorbidity. However, the availability of illegitimate online pharmacies in the market may hamper the market growth. Furthermore, the increasing adoption rate of the Internet and healthcare apps provides lucrative opportunities for the players operating in the market.

An ePharmacy—also called online pharmacy—operates via the Internet and sells items such as drugs, medicines, food supplements, cosmetics products, and medical devices. It can offer services such as ePrescribing, locating a pharmacy, services for new medications, checking stock, online consultation, ordering over-the-counter drugs online with consultation, monitoring, reminders, and management of clinical information.

The key factors driving the Europe ePharmacy market growth are the rising occurrence of chronic and infectious diseases, the increase of patients with multimorbidity, and lucrative investment for ePharmacy startups. However, the availability of illegitimate online pharmacies and data security may hamper the market’s growth. The increasing adoption rate of internet and healthcare apps creates an opportunity to propel the ePharmacy market.

Market Segmentation
Based on type, the Europe ePharmacy market is segmented into prescription and over-the-counter (OTC). The OTC segment accounted for the largest revenue contributor in 2020 with USD 6,379.00 million and is anticipated to reach USD 18,380.27 million by 2027 at a CAGR of 15.59% during the forecast period.

Based on operating platforms, the Europe ePharmacy market has been segmented into website and apps. The website segment accounted for the largest market share in 2020 and is anticipated to reach USD 19,041.40 million by 2027 at a CAGR of 15.54% during the forecast period.

Regional Analysis
Europe ePharmacy Market held the revenue share of USD 8,183.33 million in 2020 and is anticipated to grow with the CAGR with 15.79% from 2021-2027. The benefits offered by ePharmacy enable the consumers to order medications in a convenient and hassle-free fashion, right from their computer or mobile phone.

In addition, rising Internet penetration across the region, improving digitalization of healthcare services, and the growing number of tech-savvy consumers are also boosting the market growth. The COVID-19 pandemic has also impacted the purchasing behavior of consumers. The pandemic has resulted in more people than ever seeking medicines as well as other healthcare-related supplies through the ePharmacy platform.

Major Players
The key market players are Zur Rose Group (Switzerland), Shop Apotheke Europe (Netherlands), Apoteket AB (Sweden), Walgreens Boots Alliance, Inc. (US), lloydspharmacy (UK), Medpex (Germany), Medikamente-per-klick.de (Germany), apotal.de (Germany), and Viata online pharmacy (Belgium).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING OCCURRENCE OF CHRONIC AND INFECTIOUS DISEASES
4.2.2 INCREASING PATIENTS WITH MULTIMORBIDITIES
4.2.3 LUCRATIVE INVESTMENT FOR EPHARMACY STARTUPS
4.3 RESTRAINTS
4.3.1 AVAILABILITY OF ILLEGITIMATE ONLINE PHARMACIES
4.3.2 DATA SECURITY
4.4 OPPORTUNITIES
4.4.1 INCREASING ADOPTION RATE OF INTERNET AND HEALTHCARE APPS
4.5 CHALLENGES
4.5.1 REGULATORY RESTRICTIONS RELATED TO EPHARMACY

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
5.1.2 SERVICE CUSTOMIZATION
5.1.3 CUSTOMER PURCHASE SUPPORT
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON EPHARMACY MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY OF MEDICINES
5.3.3 IMPACT ON MAJOR PLAYERS
5.3.4 IMPACT ON AVAILABILITY OF PRODUCTS/SERVICES
5.4 REGULATORY LANDSCAPE FOR E-PHARMACIES IN EUROPE
5.4.1 REGULATORY LANDSCAPE BY COUNTRY

6 EUROPE EPHARMACY MARKET, BY TYPE
6.1 OVERVIEW
6.2 PRESCRIPTION
6.2.1 CHRONIC DRUGS
6.2.2 ACUTE DRUGS
6.3 OVER THE COUNTER (OTC)
6.3.1 ANALGESICS
6.3.2 COLD & COUGH REMEDIES
6.3.3 DIGESTIVE & INTESTINAL REMEDIES
6.3.4 SKIN TREATMENT
6.3.5 VITAMINS & MINERALS
6.3.6 PERSONAL CARE

7 EUROPE EPHARMACY MARKET, BY OPERATING PLATFORM
7.1 OVERVIEW
7.2 WEBSITE
7.3 APPS

8 EUROPE EPHARMACY MARKET, BY COUNTRY
8.1 OVERVIEW
8.2 GERMANY
8.3 FRANCE
8.4 UK
8.5 ITALY
8.6 SPAIN
8.7 PORTUGAL
8.8 NETHERLANDS
8.9 TURKEY
8.10 CZECH REPUBLIC
8.11 ROMANIA
8.12 LITHUANIA
8.13 NORWAY
8.14 REST OF EUROPE

9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITOR MARKET SHARE ANALYSIS, BY COUNTRY (%), 2020
9.3 COMPETITIVE BENCHMARKING
9.4 MAJOR GROWTH STRATEGY IN THE EUROPE EPHARMACY MARKET
9.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE EUROPE EPHARMACY MARKET
9.6 KEY DEVELOPMENT ANALYSIS
9.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.7.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
9.7.2 MERGER/ACQUISITION
9.7.3 PARTNERSHIP/ AGREEMENT
9.8 FINANCIAL MATRIX
9.8.1 SALES (USD MILLION), 2020
9.9 LIST OF MAJOR START-UPS

10 COMPANY PROFILES
10.1 DR. FOX PHARMACY
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCT/SERVICE OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 VIATA ONLINE PHARMACY
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCT/SERVICE OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 BESTWAY GROUP LIMITED (WELL PHARMACY)
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCT/SERVICE OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 LLOYDS PHARMACY
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCT/SERVICE OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 APOTEK AB
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCT/SERVICE OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 SHOP APOTHEKE EUROPE
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCT/SERVICE OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 DR.MAX PHARMACY
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCT/SERVICE OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 ZUR ROSE GROUP (DOCMORRIS N.V.)
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCT/SERVICE OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 MEDPEX
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCT/SERVICE OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 MEDIKAMENTE-PER-KLICK.DE
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCT/SERVICE OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
10.11 APOTAL.DE
10.11.1 COMPANY OVERVIEW
10.11.2 FINANCIAL OVERVIEW
10.11.3 PRODUCT/SERVICE OFFERED
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIES
10.12 PEARS HEALTH CYBER, SRO (LEKARNA.CZ)
10.12.1 COMPANY OVERVIEW
10.12.2 FINANCIAL OVERVIEW
10.12.3 PRODUCT/SERVICE OFFERED
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIES
10.13 FARMASIET
10.13.1 COMPANY OVERVIEW
10.13.2 FINANCIAL OVERVIEW
10.13.3 PRODUCT/SERVICE OFFERED
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIES
10.14 WALGREENS BOOTS ALLIANCE, INC. (THE BOOTS COMPANY PLC)
10.14.1 COMPANY OVERVIEW
10.14.2 FINANCIAL OVERVIEW
10.14.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
10.14.4 KEY DEVELOPMENTS
10.14.5 SWOT ANALYSIS
10.14.6 KEY STRATEGIES

11 EUROPE EPHARMACY MARKET, KEY QUESTIONS BY COUNTRY
11.1 ELECTRONIC PRESCRIPTIONS
11.2 OTC SALES
11.3 PARA-PHARMACY
11.4 ONLINE PAYMENTS
11.5 DELIVERY
11.6 CENTRAL PRICING STRATEGY
11.7 SKUS BY MARKET OF TOP COMPETITORS AND WHAT IS OVERALL 80/20 DISTRIBUTION OF SKU
11.7.1 GERMANY
11.7.2 FRANCE
11.7.3 UK
11.7.4 ITALY
11.7.5 SPAIN
11.7.6 PORTUGAL
11.7.7 TURKEY
11.7.8 NETHERLANDS
11.7.9 NORWAY
11.7.10 CZECH REPUBLIC
11.7.11 ROMANIA
11.7.12 LITHUANIA
11.8 CLICK AND COLLECT
11.9 LOYALTY CARD ALLOWED FOR OTC AND PARA
11.10 ADVERTISING AND DISCOUNTING
11.11 PRICE ANALYSIS FOR ONLINE VS BRICK AND MORTAR PHARMACIES
11.12 EUROPE EPHARMACY CONSUMER BEHAVIOR INSIGHTS
11.13 PROVIDERS ANALYSIS BY PRODUCT TYPE

12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS